Trial Profile
A Phase I, single-center, single-dose, randomized, open-label, three-way crossover, pharmacokinetic study of AP-THC (tetrahydrocannabinol)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Apr 2020
Price :
$35
*
At a glance
- Drugs Tetrahydrocannabinol (Primary)
- Indications Fibromyalgia; Pain
- Focus Pharmacokinetics
- 10 Jan 2019 According to a Intec Pharma media release, first patient has been dosed in this trial.
- 10 Jan 2019 Status changed from planning to recruiting, according to a Intec Pharma media release.
- 19 Dec 2018 According to a Intec Pharma media release, the company plans to begin this trial in the first half of 2019.